Cargando…
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 pat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037797/ https://www.ncbi.nlm.nih.gov/pubmed/27618028 http://dx.doi.org/10.3390/ijms17091520 |
_version_ | 1782455816217952256 |
---|---|
author | Schlack, Katrin Krabbe, Laura-Maria Fobker, Manfred Schrader, Andres Jan Semjonow, Axel Boegemann, Martin |
author_facet | Schlack, Katrin Krabbe, Laura-Maria Fobker, Manfred Schrader, Andres Jan Semjonow, Axel Boegemann, Martin |
author_sort | Schlack, Katrin |
collection | PubMed |
description | The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 patients, PSA-subforms were analyzed before and at 8–12 weeks under therapy as prognosticators of progression-free-survival (PFS) and overall survival (OS). Comparing patients with a PFS < vs. ≥12 months by using Mann–Whitney–Wilcoxon Tests, the relative-median-change of tPSA (−0.1% vs. −86.8%; p = 0.02), fPSA (12.1% vs. −55.3%; p = 0.03) and [−2]proPSA (8.1% vs. −59.3%; p = 0.05) differed significantly. For men with ≤ vs. >15 months of OS there was a non-significant trend for a difference in the relative-median-change of fPSA (17.0% vs. −46.3%; p = 0.06). In Kaplan–Meier analyses, declining fPSA and [−2]proPSA were associated with a longer median PFS (13 months, 95% confidence interval (CI): 9.6–16.4 vs. 10 months, 95% CI: 3.5–16.5; p = 0.11), respectively. Correspondingly, decreasing fPSA and [−2]proPSA values indicated an OS of 32 months (95% CI: not reached (NR)) compared to 21 months in men with rising values (95% CI: 7.7–34.3; p = 0.14), respectively. We concluded that the addition of fPSA- and [−2]proPSA-changes to tPSA-information might be further studied as potential markers of early Abiraterone response in mCRPC patients. |
format | Online Article Text |
id | pubmed-5037797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-50377972016-09-29 Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer Schlack, Katrin Krabbe, Laura-Maria Fobker, Manfred Schrader, Andres Jan Semjonow, Axel Boegemann, Martin Int J Mol Sci Article The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 patients, PSA-subforms were analyzed before and at 8–12 weeks under therapy as prognosticators of progression-free-survival (PFS) and overall survival (OS). Comparing patients with a PFS < vs. ≥12 months by using Mann–Whitney–Wilcoxon Tests, the relative-median-change of tPSA (−0.1% vs. −86.8%; p = 0.02), fPSA (12.1% vs. −55.3%; p = 0.03) and [−2]proPSA (8.1% vs. −59.3%; p = 0.05) differed significantly. For men with ≤ vs. >15 months of OS there was a non-significant trend for a difference in the relative-median-change of fPSA (17.0% vs. −46.3%; p = 0.06). In Kaplan–Meier analyses, declining fPSA and [−2]proPSA were associated with a longer median PFS (13 months, 95% confidence interval (CI): 9.6–16.4 vs. 10 months, 95% CI: 3.5–16.5; p = 0.11), respectively. Correspondingly, decreasing fPSA and [−2]proPSA values indicated an OS of 32 months (95% CI: not reached (NR)) compared to 21 months in men with rising values (95% CI: 7.7–34.3; p = 0.14), respectively. We concluded that the addition of fPSA- and [−2]proPSA-changes to tPSA-information might be further studied as potential markers of early Abiraterone response in mCRPC patients. MDPI 2016-09-09 /pmc/articles/PMC5037797/ /pubmed/27618028 http://dx.doi.org/10.3390/ijms17091520 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schlack, Katrin Krabbe, Laura-Maria Fobker, Manfred Schrader, Andres Jan Semjonow, Axel Boegemann, Martin Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer |
title | Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer |
title_full | Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer |
title_fullStr | Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer |
title_full_unstemmed | Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer |
title_short | Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer |
title_sort | early prediction of therapy response to abiraterone acetate using psa subforms in patients with castration resistant prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037797/ https://www.ncbi.nlm.nih.gov/pubmed/27618028 http://dx.doi.org/10.3390/ijms17091520 |
work_keys_str_mv | AT schlackkatrin earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer AT krabbelauramaria earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer AT fobkermanfred earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer AT schraderandresjan earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer AT semjonowaxel earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer AT boegemannmartin earlypredictionoftherapyresponsetoabirateroneacetateusingpsasubformsinpatientswithcastrationresistantprostatecancer |